We demonstrate the utility of this methodology in the context of chronic myeloid leukemia (CML), where longitudinal monitoring of BCR::ABL1 transcript levels guides treatment decisions. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.